@kulvinderlall Look at this paper - horrible results after 5 years - certainly not a reason to implant tissue valves in younger patients https://t.co/L338qn9udu
RT @yt_reggae: TAVIの長期成績について。TAVIは短期的な成績は治療対象が手術リスク低リスクであれ、生体弁機能不全であっても良好ですが、長期成績は? TAV in SAVの観察研究は慢性期に明らかにTAVIがイベント多くて、redo SAVRできる症例と年齢な…
RT @yt_reggae: TAVIの長期成績について。TAVIは短期的な成績は治療対象が手術リスク低リスクであれ、生体弁機能不全であっても良好ですが、長期成績は? TAV in SAVの観察研究は慢性期に明らかにTAVIがイベント多くて、redo SAVRできる症例と年齢な…
RT @yt_reggae: TAVIの長期成績について。TAVIは短期的な成績は治療対象が手術リスク低リスクであれ、生体弁機能不全であっても良好ですが、長期成績は? TAV in SAVの観察研究は慢性期に明らかにTAVIがイベント多くて、redo SAVRできる症例と年齢な…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @HeartOTXHeartMD: French admin hospital-discharge database; study collected information for Pts treated for #aorticbioprosthesis failure…
RT @HeartOTXHeartMD: French admin hospital-discharge database; study collected information for Pts treated for #aorticbioprosthesis failure…
French admin hospital-discharge database; study collected information for Pts treated for #aorticbioprosthesis failure with isolated #VIVTAVR or #redo #SAVR between 2010 and 2019. Propensity score matching was used for the analysis of outcomes. Nice audio
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
Nice study @deharo_pierre et al!
RT @edurontoFF: .Valve in Valve TAVR vs SAVR .Muerte CV, ACV, Infarto, o rehosp. por IC sin diferencias (OR: 1.18; IC 0.99-1.41; p=0.26) a…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @edurontoFF: .Valve in Valve TAVR vs SAVR .Muerte CV, ACV, Infarto, o rehosp. por IC sin diferencias (OR: 1.18; IC 0.99-1.41; p=0.26) a…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
.Valve in Valve TAVR vs SAVR .Muerte CV, ACV, Infarto, o rehosp. por IC sin diferencias (OR: 1.18; IC 0.99-1.41; p=0.26) a 516 días .Rehosp a largo plazo por IC y MCP mayor en TAVR. Estrategia viable y segura? Opiniones? @Argenscore @omendiz @SAC_54 @SIAC
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
RT @JACCJournals: Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: http…
Valve-in-valve #TAVR: Perhaps a better alternative than re-do #SAVR? Dr. @Deharo_Pierre et al. investigate in #JACC: https://t.co/ZoJkQt3b60 https://t.co/RP9s1uDQkt
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
RT @GilbertTangMD: Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cro…
Great @JACCJournals paper showing VIV #TAVR may do better early than redo SAVR but not so much over time with curves cross over. Need informed discussion with lower risk and younger pts where valve durability & optimal timing of reop matter. @DrMoritzW
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
RT @abelcasso: Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement. TAVR was associated with…
RT @ArashArya_EP: VIV #TAVR: Major cardiovascular outcomes were not different between the 2 treatments (#SAVR vs. #TAVR) during long-term f…
VIV #TAVR: Major cardiovascular outcomes were not different between the 2 treatments (#SAVR vs. #TAVR) during long-term follow-up. https://t.co/5XrzNEWMXe https://t.co/eDZgle5Vo4
Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement | JACC: Journal of the American College of Cardiology. 👏🏻👏🏻👏🏻👏🏻 https://t.co/qhTSGLq9Oz
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement | JACC: Journal of the American College of Cardiology https://t.co/goIzZpyFuL
RT @deharo_pierre: Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm http…
Hot of the press 🔥🔥VIV TAVI vs. redo SAVR in failed aortic bioprosthesis | JACC. @PCRonline @JACCJournals @aphm https://t.co/SPhqeJIz3A
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement | JACC: Journal of the American College of Cardiology https://t.co/blCHrHZXb9
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @Chestcracker: redo SAVR or Valve -in-Valve #TAVR for structural deterioration of aortic tissue prostheses ? @brheartvalvesoc https://t.…
redo SAVR or Valve -in-Valve #TAVR for structural deterioration of aortic tissue prostheses ? @brheartvalvesoc https://t.co/58YMfnceao
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
RT @Susumu_Manabe: 壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。htt…
RT @BartsEcho: Valve-in-valve TAVR versus redo surgical AVR for bioprosthesis failure. No difference in medium term outcomes https://t.c…
RT @Susumu_Manabe: 壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。htt…
valve in valveを見越した中高年への生体弁の適応はある程度慎重にならざるをえないのかもしれませんね
RT @M_Pompeu_Sa_MD: 🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartVal…
🔥Hot off the press🔥 New French paper in the scenario of ViV-TAVI versus Redo-SAVR!!! https://t.co/tlxsgdDU24 @HeartValveOrg @tssmn @GilbertTangMD @TsuyoshiKaneko1 @KendraGrubb @igeorge1975 @msimonatomd @OuzounianMD @derrickytam @adnanalkhouli @crfheart @P
RT @Susumu_Manabe: 壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。htt…
RT @Susumu_Manabe: 壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。htt…
RT @Susumu_Manabe: 壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。htt…
壊れた生体弁に対するカテーテル的大動脈弁移植術(TAVR)、いわゆるvalve in valve。外科的弁置換(SAVR)と比べて短期成績はよいが、遠隔期では心不全入院などがTAVRに多く、術後4年の イベント発症率は2群で変わらず。https://t.co/z12nPxMtes https://t.co/pkvSTgGXkx
Valve-in-valve TAVR versus redo surgical AVR for bioprosthesis failure. No difference in medium term outcomes https://t.co/BVPWQGbgoT https://t.co/R3zXeJvVAP